Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Daiichi Sankyo Head Apologizes For, Defends Buy Of India's Ranbaxy

This article was originally published in PharmAsia News

Executive Summary

Daiichi Sankyo's Takashi Shoda apologized for harming shareholder equity with the company's purchase of India's Ranbaxy Laboratories, but said he was confident the move would pay off in the medium to long term. The head of Daiichi Sankyo said in an interview the timing of the expensive buy just before the financial crisis and then a Ranbaxy plant encountering problems with the U.S. FDA caused him to make several management changes. Shoda stressed that now that Malvinder Singh has departed Ranbaxy, Shoda is overseeing Ranbaxy and is aware of its problems. Shoda also said he learned of Ranbaxy problems with the FDA before the deal was closed, but noted the United States accounted for only a quarter of the Indian company's total sales. (Click here for more

You may also be interested in...



New EU Filings

Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

BMS Has A Strong Pipeline, But Access Challenges Remain

Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.

Novartis Nominates Ex-BMS Chief As It Pursues US Growth Strategy

The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.

Latest Headlines
See All
UsernamePublicRestriction

Register

SC072570

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel